Casi Pharmaceuticals Inc (CASI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2016 | 09-2016 | 06-2016 | 03-2016 | 12-2015 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 27,093 | 24,137 | 18,535 | 13,945 | 5,131 |
| TOTAL | $27,449 | $24,538 | $18,765 | $14,264 | $5,569 |
| Non-Current Assets | |||||
| PPE Net | 230 | 184 | 169 | 223 | 219 |
| Other Non-Current Assets | 35 | 35 | 35 | 38 | 38 |
| TOTAL | $264 | $219 | $203 | $261 | $257 |
| Total Assets | $27,713 | $24,757 | $18,968 | $14,525 | $5,826 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | 1,472 | N/A |
| Accounts payable and accrued liabilities | 1,065 | 919 | 946 | 783 | 884 |
| Accrued Expenses | 251 | 162 | 161 | 158 | 170 |
| TOTAL | $1,316 | $2,567 | $2,586 | $2,413 | $1,054 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,491 | N/A | N/A | N/A | 1,465 |
| Other Non-Current Liabilities | 4,122 | 6,167 | 6,358 | 7,475 | 9,395 |
| TOTAL | $5,614 | $6,167 | $6,358 | $7,475 | $10,860 |
| Total Liabilities | $6,929 | $8,734 | $8,944 | $9,888 | $11,914 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 6,020 | 6,020 | 4,946 | 4,258 | 4,258 |
| Common Shares | 603 | 6,769 | 476 | 427 | 325 |
| Retained earnings | -441,932 | -439,258 | -437,565 | N/A | -432,478 |
| Other shareholders' equity | -34 | -34 | -34 | -434,307 | -34 |
| TOTAL | $20,784 | $16,023 | $10,024 | $4,637 | $-6,087 |
| Total Liabilities And Equity | $27,713 | $24,757 | $18,968 | $14,525 | $5,826 |